In 2013, OncoMed and Celgene Corporation announced a broad strategic collaboration on research and development programs directed to the discovery
and development of novel biologic therapeutics. Through the collaboration Celgene has an exclusive option to OncoMed's etigilimab
(anti-TIGIT, OMP-313M32) program. The collaboration includes a significant option exercise payment and payments for achievement
of development, regulatory and commercial milestones. OncoMed will also receive royalty payments based on future
In 2010, OncoMed entered into a strategic alliance with Bayer to discover, develop and commercialize novel anti-cancer therapeutics. The collaboration with Bayer is currently focused on small molecules targeting the Wnt signaling pathway. Bayer leads discovery and development efforts for the small molecules and is obligated to make payments to OncoMed upon achievement of certain research development, regulatory and commercial milestones for small molecule therapeutics. OncoMed will also receive royalties from Bayer on future product sales of the small molecule therapeutics.